News Sentiment

SPRO sentiment intelligence

Spero Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.10 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-4.5% over one week, -26.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.5% Price reacting lower
Trend fit Trend inactive -26.3% over four weeks
Fair value 25.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 39
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
GuruFocus 6
Market source 6
TradingView 5
Seeking Alpha 4
simplywall.st 4
GlobeNewswire 3
Investing.com UK 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Deals and strategy 9
Regulatory and legal 6
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Stock Titan Direct company coverage

Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan

Spero Therapeutics' stockholders approved a new 2026 Stock Incentive Plan covering up to 12,895,866 shares and doubled the authorized common stock from 120,000,000 to 240,000,000 shares. These actions provide the company with greater flexibility for future equity awards and poten

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:40
Source
Stock Titan
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options

Spero Therapeutics director Frank E. Thomas received equity awards comprising 10,000 restricted stock units (RSUs) and options to purchase 20,000 shares of common stock at an exercise price of $2.15 per share. Both the RSUs and options are set to vest on June 23, 2027, contingent

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:09
Source
Stock Titan
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant

Spero Therapeutics director John C. Pottage Jr. was granted 10,000 restricted stock units (RSUs) and a stock option for 20,000 shares, as detailed in a recent Form 4 filing. The RSUs and stock options are set to vest on June 23, 2027, contingent upon his continued service as a di

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:09
Source
Stock Titan
Investing.com UK Direct company coverage

Form 4 Spero Therapeutics Inc For: 25 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Spero Therapeutics Inc. related to activity on June 25th. It is a brief, factual announcement without further details provided within the content. The article primarily serves as a placeholder for a financial filing a

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:02
Source
Investing.com UK
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) director awarded RSUs and stock options

Spero Therapeutics director Patrick V.J.J. Vink was granted 10,000 restricted stock units (RSUs) and options for 20,000 shares, as detailed in a recent SEC Form 4 filing. The RSUs and stock options vest on June 23, 2027, with the options having an exercise price of $2.15 per shar

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant

Spero Therapeutics director Cynthia Smith was granted 10,000 Restricted Stock Units (RSUs) and a stock option for 20,000 shares of common stock. These equity awards, with an exercise price of $2.15 per share for the options, are compensation-related and will vest on June 23, 2027

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) director receives RSU and stock option awards

Spero Therapeutics director Kathleen Tregoning was granted 10,000 restricted stock units (RSUs) and stock options for 20,000 shares of common stock. The RSUs vest on June 23, 2027, and the stock options, with an exercise price of $2.1500 per share, also vest on June 23, 2027, and

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:40
Source
Stock Titan
MarketBeat Direct company coverage

Spero Therapeutics (SPRO) Short Interest & Short Float | Updated Jun 2026

As of June 15, 2026, Spero Therapeutics (SPRO) had a short interest of 1.83 million shares, representing 3.26% of its public float, marking a 7.33% increase from the previous report. The short interest ratio is 2.3 days to cover, indicating it would take 2.3 days to cover all sho

Tone
Negative 37/100
Event
Market update
Published
25 Jun 2026 18:11
Source
MarketBeat
TradingView Direct company coverage

SPRO Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Spero Therapeutics, Inc. (SPRO) stock, with analysts estimating a maximum price of $4.00. It also covers SPRO's current stock performance, volatility, market capitalization, earnings, and financial data. The information present

Tone
Negative 39/100
Event
Earnings
Published
25 Jun 2026 14:40
Source
TradingView
Kalkine Media Direct company coverage

Spero Therapeutics Stock: Antibiotic Development In Focus

Spero Therapeutics (SPRO) is under scrutiny due to its antibiotic development programs and regulatory advancements in the field of infectious disease treatment. The company is primarily known for its clinical-stage efforts in developing treatments for infectious diseases. The pro

Tone
Positive 67/100
Event
Regulatory and legal
Published
18 Jun 2026 18:40
Source
Kalkine Media
TradingKey Direct company coverage

Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Spero Therapeutics Inc. (SPRO), detailing its business segments and regional revenue contributions. The company's revenue primarily comes from Collaboration Revenue Related Party (70.41%), Collaboration Revenue (18.84%), and Grant Rev

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:10
Source
TradingKey
Stock Titan Direct company coverage

FDA approves first oral carbapenem for complicated UTIs in adults

The FDA has approved Utebzi (tebipenem pivoxil) by Spero Therapeutics and GSK, making it the first oral carbapenem for treating complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited oral treatment options. This approval is based on the PIV

Tone
Positive 72/100
Event
Regulatory and legal
Published
17 Jun 2026 16:10
Source
Stock Titan
Moomoo Direct company coverage

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

GSK and Spero Therapeutics have received FDA approval for Utebzi (tebipenem HBr) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults. This approval marks the first oral carbapenem antibiotic to be approved in the U.S. and offers a

Tone
Positive 72/100
Event
Regulatory and legal
Published
17 Jun 2026 16:10
Source
Moomoo
www.timothysykes.com Direct company coverage

SPRO Stock Slumps As Volatility Grips Small-Cap Biotech

Spero Therapeutics Inc. (SPRO) stock has fallen by 15.16% due to clinical and regulatory uncertainty, despite a strong cash position and minimal debt. The article highlights the stock's high volatility, with significant intraday price swings, making it attractive to active trader

Tone
Negative 37/100
Event
Balance sheet
Published
17 Jun 2026 15:32
Source
www.timothysykes.com